Erasca, Inc. filings document a clinical-stage oncology issuer focused on RAS/MAPK pathway-driven cancers and common stock listed on the Nasdaq Global Select Market. Recent Form 8-K reports disclose ERAS-0015 clinical data from AURORAS-1 and JYP0015M101, Regulation FD materials, financial results, cash and marketable-securities information, and common-stock offering activity under a shelf registration statement.
Proxy materials cover annual meeting procedures, director elections, executive compensation, and stockholder voting matters. Other event reports record intellectual-property correspondence involving ERAS-0015 and provide formal updates on the company's pipeline, capital structure, and public-company governance.
Erasca, Inc. entered into an underwriting agreement for a primary underwritten public offering of 31,428,572 shares of common stock at $17.50 per share. Underwriters will purchase the shares at $16.45 per share and have a 30-day option to buy up to 4,714,285 additional shares at the public price, less discounts.
The offering, made off an automatically effective Form S-3 shelf, is expected to generate net proceeds of approximately $516.0 million, or $593.5 million if the option is fully exercised, and to close on July 15, 2026 subject to customary conditions. Erasca plans to use the proceeds, together with existing cash, to fund research and development of its oncology product candidates, other development programs, and for working capital and general corporate purposes.
Erasca, Inc. is offering 31,428,572 shares of its common stock at $17.50 per share, for gross proceeds of $550,000,010, with an underwriters’ 30‑day option for up to 4,714,285 additional shares. Estimated net proceeds are about $516.0 million, to fund RAS/MAPK‑focused research and development, other development programs, working capital and general corporate purposes, and potentially in‑licensing or acquisitions. Based on 310,806,888 shares outstanding as of March 31 2026, the company calculates an as‑adjusted net tangible book value of $2.66 per share, implying $14.84 per‑share dilution to new investors. A separate at‑the‑market program still has $200 million of capacity.
Erasca is a clinical‑stage precision oncology company targeting RAS/MAPK pathway‑driven cancers, with clinical programs ERAS‑0015 and ERAS‑4001 and discovery asset ERAS‑12. Updated AURORAS‑1 Phase 1 data for ERAS‑0015 in RAS‑mutant solid tumors show treatment‑related rash in 72% of 72 patients, diarrhea in 32%, stomatitis in 19%, nausea in 14%, and no treatment‑related adverse events leading to dose discontinuations.
Erasca, Inc. is conducting a primary offering of $500,000,000 of common stock under its shelf registration, with underwriters holding a 30‑day option to buy up to an additional $75,000,000. Its common stock trades on the Nasdaq Global Select Market under the symbol “ERAS,” last reported at $18.53 on July 10, 2026.
Shares outstanding were 310,806,888 as of March 31, 2026; this is a baseline figure, not the amount being offered, and excludes any shares from this transaction or up to $200 million available under an at‑the‑market Sales Agreement. The company is a clinical‑stage precision oncology developer targeting RAS/MAPK‑driven cancers, with clinical programs ERAS‑0015 (pan‑RAS molecular glue) and ERAS‑4001 (pan‑KRAS inhibitor) plus discovery program ERAS‑12. Net proceeds, together with existing cash, will fund research and development, working capital, general corporate purposes and potential in‑licensing or acquisitions.
Erasca highlights that new investors will experience immediate and substantial dilution relative to net tangible book value of $393.5 million, or $1.27 per share, as of March 31, 2026. Updated preliminary AURORAS‑1 Phase 1 data for ERAS‑0015 in 72 patients with RAS‑mutant NSCLC and PDAC treated at 16–32 mg showed treatment‑related rash in 72% and diarrhea in 32% of patients.
Erasca, Inc. reported updated preliminary Phase 1 data from the ongoing AURORAS-1 trial of ERAS-0015, described as a potentially best-in-class, pan-RAS molecular glue in patients with RAS-mutant solid tumors. The update adds patients and longer follow-up to earlier April 2026 results.
Among 72 patients with RAS-mutant NSCLC and pancreatic ductal adenocarcinoma treated at the protocol-amended dose, treatment-related adverse events were mainly low grade. Rash occurred in 52 patients (72%), diarrhea in 23 (32%), stomatitis in 14 (19%), and nausea in 10 (14%). Events led to dose interruptions in 9 patients (13%) and dose reductions in 6 (8%), with no treatment-related adverse events causing discontinuation.
The company highlights encouraging monotherapy responses in second-line or later KRAS G12X pancreatic ductal adenocarcinoma, promising combination potential with panitumumab in metastatic colorectal cancer, and plans to accelerate potentially registration-enabling studies. Extensive risk disclosures emphasize that these are interim, forward-looking assessments subject to delay, changing data, regulatory feedback, safety and efficacy outcomes, intellectual property disputes, and funding constraints.
Erasca, Inc., a Delaware-based clinical-stage precision oncology company focused on therapies for RAS/MAPK pathway–driven cancers, has filed an automatic shelf registration as a well-known seasoned issuer. The shelf allows Erasca to offer, from time to time after effectiveness, various securities, including common stock, preferred stock, debt securities, warrants and units, with specific terms and amounts to be set in future prospectus supplements. Any securities may be sold through underwriters, dealers, agents, directly to investors, or a combination of these methods.
As of March 31, 2026, Erasca’s authorized capital stock consists of 800,000,000 shares of common stock and 80,000,000 shares of preferred stock. Its common stock trades on the Nasdaq Global Select Market under the symbol ERAS, with a last reported price of $18.53 per share on July 10, 2026. The company’s pipeline includes two clinical-stage programs, ERAS-0015 (a pan-RAS molecular glue) and ERAS-4001 (a pan-KRAS inhibitor), plus ERAS-12 (an EGFR D2/D3 biparatopic antibody) in discovery. The filing also describes existing registration rights that permit certain holders to demand registrations for offerings of at least $20.0 million on Form S-1 and $5.0 million on Form S-3, with those rights expiring in August 2026, as well as anti-takeover and forum-selection provisions.
Erasca, Inc. held its annual meeting of stockholders on June 26, 2026. As of the April 27, 2026 record date, 310,965,971 shares were entitled to vote, and 266,073,906 shares were represented in person or by proxy, establishing a strong quorum.
Stockholders elected three Class II directors—Alexander W. Casdin, Julie Hambleton, M.D., and Michael D. Varney, Ph.D.—to three-year terms expiring at the 2029 annual meeting. Votes for these nominees ranged from 219,569,944 to 223,863,013, with 25,593,152 to 29,886,221 withheld and 16,617,741 broker non-votes.
Stockholders also ratified the appointment of KPMG LLP as Erasca’s independent registered public accounting firm for the fiscal year ending December 31, 2026, with no broker non-votes recorded for this proposal.
Erasca, Inc. director Valerie Denise Harding received a stock option grant covering 29,888 shares of Common Stock. The options have an exercise price of $16.01 per share and expire on June 26, 2036.
All 29,888 options vest on June 26, 2027, provided she remains in continuous service with the company through that date. Following this grant, she holds 29,888 derivative securities directly, reflecting a routine, compensation-related award rather than an open-market purchase or sale.
Erasca, Inc. director Jean I. Liu received a stock option grant covering 29,888 shares of common stock on June 26, 2026. The option has an exercise price of $16.01 per share and expires on June 26, 2036. According to the filing, Liu now holds options for 29,888 shares following this award. The grant vests 100% on June 26, 2027, subject to her continuous service with the company until that date, and represents equity compensation rather than an open-market purchase or sale.
Erasca, Inc. director Pratik S. Multani received a stock option grant covering 29,888 shares of common stock. The option has an exercise price of $16.01 per share and expires on June 26, 2036.
All of these options vest on June 26, 2027, as long as the director continues to serve the company through that date. After this grant, the filing shows 29,888 option shares held directly, with no remaining prior derivative positions listed.
Erasca, Inc. director Alexander W. Casdin received a grant of stock options covering 29,888 shares of common stock. The options have an exercise price of $16.01 per share, expire on June 26, 2036, and vest 100% on June 26, 2027, contingent on his continued service.